{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:54:35Z","timestamp":1791060875835,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dmd.2026.100400","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:27:03Z","timestamp":1788910023000},"page":"100400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repaglinide metabolism by human hepatocytes reveals CYP2C8 dominance and misassignment of CYP3A4 by liver subcellular fractions and recombinant enzymes"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1483-2161","authenticated-orcid":false,"given":"Tashinga E.","family":"Bapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dmd.2026.100400_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.0306-5251.2003.01862.x","article-title":"CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide","volume":"56","author":"Bidstrup","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.dmd.2026.100400_bib2","article-title":"Corrigendum to \"Human cytochrome P4502C8 metabolizes repaglinide to 4'-hydroxyrepaglinide, not 3'-hydroxyrepaglinide\" [Drug Metab Dispos. 2025;53:100177]","volume":"53","author":"Sharma","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100400_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/11207600-000000000-00000","article-title":"Repaglinide: a review of its use in type 2 diabetes mellitus","volume":"72","author":"Scott","year":"2012","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.dmd.2026.100400_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2337\/diabetes.47.3.345","article-title":"Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes","volume":"47","author":"Fuhlendorff","year":"1998","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.dmd.2026.100400_bib5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/clpt.2010.358","article-title":"Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans","volume":"89","author":"Honkalammi","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.dmd.2026.100400_bib6","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1124\/dmd.111.040931","article-title":"Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses","volume":"39","author":"Honkalammi","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100400_bib7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0009-9236(03)00228-5","article-title":"Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide","volume":"74","author":"Niemi","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100400_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/clpt.2008.34","article-title":"The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo","volume":"84","author":"Tornio","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100400_bib9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clpt.2005.07.005","article-title":"Cyclosporine markedly raises the plasma concentrations of repaglinide","volume":"78","author":"Kajosaari","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.dmd.2026.100400_bib10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.112.045286","article-title":"A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance","volume":"40","author":"Sall","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100400_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s002280050667","article-title":"Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing","volume":"55","author":"van Heiningen","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100400_bib12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2125.2010.03772.x","article-title":"Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism","volume":"70","author":"Gan","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100400_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/152091599317143","article-title":"Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes","volume":"1","author":"Strange","year":"1999","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100400_bib14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2125.2008.03287.x","article-title":"The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range","volume":"66","author":"Kalliokoski","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100400_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mcp.2001.116511","article-title":"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide","volume":"70","author":"Niemi","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100400_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00125-003-1034-7","article-title":"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide","volume":"46","author":"Niemi","year":"2003","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.dmd.2026.100400_bib17","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s42003-025-08903-1","article-title":"A mismatch in enzyme-redox partnerships underlies divergent cytochrome P450 activities between human hepatocytes and microsomes","volume":"8","author":"Bapiro","year":"2025","journal-title":"Commun Biol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100400_bib18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/cpdd.1224","article-title":"A phase 1 study to evaluate absolute bioavailability and absorption, distribution, metabolism, and excretion of savolitinib in healthy male volunteers","volume":"12","author":"Miah","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"10.1016\/j.dmd.2026.100400_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/bcp.14994","article-title":"Clinical evaluation of the potential drug-drug interactions of savolitinib: interaction with rifampicin, itraconazole, famotidine or midazolam","volume":"88","author":"Ren","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100400_bib20","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/dmd.123.001323","article-title":"The disconnect in intrinsic clearance determined in human hepatocytes and liver microsomes results from divergent cytochrome P450 activities","volume":"51","author":"Bapiro","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100400_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/dmd.121.000758","article-title":"Intersystem extrapolation factors are substrate-dependent for CYP3A4: impact on cytochrome P450 reaction phenotyping","volume":"50","author":"Dantonio","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100400_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/jpet.117.240523","article-title":"Physiologically based pharmacokinetic model of all-trans-retinoic acid with application to cancer populations and drug interactions","volume":"361","author":"Jing","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100400_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1124\/dmd.110.035147","article-title":"Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450","volume":"39","author":"Chen","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100400_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejmech.2012.06.043","article-title":"Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design","volume":"57","author":"Di","year":"2012","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/j.dmd.2026.100400_bib25","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1124\/dmd.106.010793","article-title":"Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes","volume":"34","author":"Lu","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100400_bib26","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1021\/acs.molpharmaceut.1c00053","article-title":"Influence of proteome profiles and intracellular drug exposure on differences in CYP activity in donor-matched human liver microsomes and hepatocytes","volume":"18","author":"Wegler","year":"2021","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.dmd.2026.100400_bib27","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1007\/s11095-010-0218-3","article-title":"Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view","volume":"27","author":"Hallifax","year":"2010","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.dmd.2026.100400_bib28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0887-2333(94)90002-7","article-title":"Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics","volume":"8","author":"Houston","year":"1994","journal-title":"Toxicol In Vitro"},{"issue":"9","key":"10.1016\/j.dmd.2026.100400_bib29","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1124\/dmd.120.000017","article-title":"Application of azamulin to determine the contribution of CYP3A4\/5 to drug metabolic clearance using human hepatocytes","volume":"48","author":"Chanteux","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100400_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100223","article-title":"Fraction metabolized by cytochrome P450 enzymes: a comprehensive evaluation of the translatability of an in vitro HepatoPac assay","volume":"54","author":"Klammers","year":"2026","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100400_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.104.002766","article-title":"Selective inhibition of human cytochrome P4502C8 by montelukast","volume":"33","author":"Walsky","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100400_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \"pie\"","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100400_bib33","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/clpt.2011.313","article-title":"Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses","volume":"91","author":"Honkalammi","year":"2012","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:17:08Z","timestamp":1791058628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0090955626006690"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100400","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repaglinide metabolism by human hepatocytes reveals CYP2C8 dominance and misassignment of CYP3A4 by liver subcellular fractions and recombinant enzymes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100400"}}